Figure 2 presents a summary of biologics targeting type 2 inflammation in CRSwNP. An investigational IL-4Rα inhibitor, rademikibart (CBP-201), began investigation in a clinical trial in patients with CRSwNP in 2021, but the trial was terminated owing to enrollment challenges (94). Here, IL4R is linked to chronic rhinosinusitis with nasal polyps.